Methamphetamine users in sustained abstinence: A proton magnetic resonance spectroscopy study

Archives of General Psychiatry

Volumn 62, Issue 4, 2005, Pages 444-452

  Nordahl, Thomas E ^a,b,f   Salo, Ruth ^a,b   Natsuaki, Yutaka ^b,e   Galloway, Gantt P ^c   Waters, Christy ^d   Moore, Charles D ^d   Kile, Shawn ^a   Buonocore, Michael H ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Haight Ashbury Free Clinics   (United States)

^d Kaiser Chem Dependence Recovery P   (United States)

^e University of California   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; DRUG METABOLITE; METHAMPHETAMINE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DEPENDENCE; DRUG WITHDRAWAL; FEMALE; FRONTAL CORTEX; HUMAN; MALE; OUTPATIENT; PROTON NUCLEAR MAGNETIC RESONANCE; VISUAL CORTEX;

ADULT; AMBULATORY CARE; AMPHETAMINE-RELATED DISORDERS; ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; DOPAMINE; FEMALE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHAMPHETAMINE; PHOSPHOCREATINE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE WITHDRAWAL SYNDROME; TISSUE DISTRIBUTION; VISUAL CORTEX;

EID: 16344364487     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.62.4.444     Document Type: Article

References (77)

1. Bowyer JF, Frame LT, Clausing P, Nagamoto-Combs K, Osterhout CA, Sterling CR, Tank AW. Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J Pharmacol Exp Ther. 1998;286: 1074-1085.
2. Chapman DE, Hanson GR, Kesner RP, Keefe KA. Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther. 2001;296:520-527.
3. Johnson-Davis KL, Hanson GR, Keefe KA. Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression. J Neurochem. 2002;82:1472-1479.
4. Ricaurte GA, Schuster CR, Seiden LS. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 1980;193:153-163.
5. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. Dopamine nerve terminal degeneration produced by high doses of methamphetamine in the rat brain. Brain Res. 1982;235:93-103.
6. Ricaurte GA, Seiden LS, Schuster CR. Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine. Neuropharmacology. 1983;22:1383-1388.
7. Ricaurte GA, Seiden LS, Schuster CR. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 1984;303:359-364.
8. Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WB, Ravert HT, Musachio J, McCann UD, Ricaurte GA. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci. 1998; 18:419-427.
9. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980;181: 151-160.
10. Axt KJ, Molliver ME. Immunocytochemical evidence for methamphetamine- induced serotonergic axon loss in the rat brain. Synapse. 1991;9:302-313.
11. Haughey HM, Fleckenstein AE, Hanson GR. Differential regional effects of methamphetamine on activities of tryptophan and tyrosine hydroxylase. J Neurochem. 1999;72:661-668.
12. Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther. 1980;214:257-262.
13. O'Hearn E, Battaglia G, De Souza EB, Kuhar MH, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminais in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988;8:2788-2803.
14. Sabol KE, Richards JB, Yung K. The effects of high-dose methamphetamine in the aging rat: differential reinforcement of low-rate 72-s schedule behavior and neurochemistry. J Pharmacol Exp Ther. 2000;294:850-863.
15. Zhou FC, Bledsoe S. Methamphetamine causes rapid varicosis, perforation and definitive degeneration of serotonin fibers: an immunocytochemical study of serotonin transporter. 1996;1:009. Available at: http://www.neuroscience.com/ manuscripts-1996/1996-009-zhou/1996-009-zhou.html.
16. Melega WP, Quintana J, Raleigh MJ, Stout DB, Yu DC, Lin KP, Huang SC, Phelps ME. 6-[F-18]Fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Synapse. 1996;22:63-69.
17. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Varughese K, Newton T, Woods R, Rawson R, Ling W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73-84.
18. Cass WA, Manning MW. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci. 1999; 19:7653-7660.
19. Fischer C, Hatzidimitrous G, Wlos J, Ricaurte GA. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4 methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci. 1995; 15:5476-5485.
20. Harvey DC, Lacan G, Tanious SP, Malega WP. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res. 2000;871:259-270.
21. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998;18:8417-8422.
22. Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Carthy T, London M, Deakin JFW, Sahakian BJ, Robbins TW. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology. 1999;20:322-339.
23. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001; 21:9414-9418.
24. Wang GJ, Volkow N, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler JS. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry. 2004;161:242-248.
25. Wilson JM, Kalasinshy KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2:699-703.
26. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Galley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377-382.
27. Cecil KM, Lenkinski RE, Meaney DF, McIntosh TK, Smith DH. High-field proton magnetic resonance spectroscopy of a swine model for axonal injury. J Neurochem. 1998;70:2038-2044.
28. Sager TN, Topp S, Torup L, Hanson LH, Egestad B, Moller A. Evaluation of CA1 damage using single-voxel 1H-MRS and un-biased stereology: can non-invasive measures of N-acetyl-aspartate following global ischemia be useful as a reliable measure of neuronal damage? Brain Res. 2001;892:166-175.
29. Gonen O, Catalaa I, Bann JS, Ge Y, Mannon LJ, Kolson DL, Grossman RI. Total brain N-acetylaspartate: a new measure of disease in MS. Neurology. 2000; 54:15-19.
30. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45:37-45.
31. Tsai G, Coyle JT. N-acetylasparatate in neuropsychiatric disorders. Prog Neurobiol. 1995;46:531-540.
32. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 NMR spectroscopy. Radiology. 1997;203:829-836.
33. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer's disease. Magn Reson Med. 1994; 32:110-115.
34. Pfefferbaum A, Adalsteinsson A, Spielman D, Sullivan EV, Lim KO. In vivo brain concentrations of N-acetyl compounds, creatine and choline in Alzheimer's disease. Arch Gen Psychiatry. 1999;56:185-192.
35. Ende GR, Laxer KD, Knowlton RC, Matson GB, Schuff N, Fein G, Weiner MW. Temporal lobe epilepsy: bilateral hippocampal metabolite changes revealed at proton MR spectroscopic imaging. Radiology. 1997;202:809-817.
36. Chang L, Miller BL, McBride D, Cornford M, Oropilla G, Buchthal S, Chiang F, Aronow H, Beck CK, Ernst T. Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology. 1995;197:525-531.
37. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolites correlate with clinical severity of HIV-cognitive motor complex. Neurology. 1999; 52:100-108.
38. Fein G, Meyerhoff D, Di Sclafani V, Ezekiel F, Poole N, MacKay S, Dillon WP, Constans J-M, Weiner MW. 1H magnetic resonance spectroscopic imaging separates neuronal from glial changes in alcohol-related brain atrophy. In: Lancaster F, ed. Alcohol and Glial Cells, NIMA Research Monograph #27. Bethesda, Md: National Institutes of Health; 1994:227-241.
39. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5:303-324.
40. Ott D, Hennig J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology. 1993;186:745-752.
41. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Haenicke W, Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Magn Reson Med. 1989;9:126-131.
42. Friedman SD, Brooks WM, Jung RE, Chiulli SJ, Sloan JH, Montoya BT, Hart BL, Yeo RA. Quantitative proton MRS predicts outcome after traumatic brain injury. Neurology. 1999;52:1384-1391.
43. Barker PB, Breiter SN, Soher BJ. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med. 1994;32:157-163.
44. Miller G, Gainet-Dinov R, Levey A, Caron M. Dopamine transporters and neuronal injury. Trends Pharmacol Sci. 1999;20:424-429.
45. Tedeschi G, Battalion A, Lundbom N, Bonavita S, Patronas NJ, Duyn JH, Metman LV, Chase TN, Di Chiro G. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology. 1996;47:696-704.
46. Lim KO, Adalsteinsson A, Spielman D, Rosenbloom MJ, Sullivan EV, Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry. 1998;55:346-352.
47. Pfefferbaum A, Adalsteinsson A, Spielman D, Sullivan EV, Lim KO. In vivo spectroscopic quantification of the N-acetyl moiety, creatine and choline from large volumes of gray and white matter: Effects of normal aging. Magn Reson Med. 1999;41:276-284.
48. Tedeschi G, Bertolino A, Righini A, Campbell G, Raman R, Duyn JH, Moonen CTW, Alger JR, Di Chiro G. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology. 1995;45:1384-1391.
49. Chang L, Ernst T, Poland RE, Jenden DJ. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci. 1996;58:2049-2056.
50. Doyle TJ, Beddell BJ, Narayana PA. Relative concentration of proton MR visible neurochemicals in gray and white matter in human brain. Magn Reson Med. 1995; 33:755-759.
51. Narayana PA, Fotedar LK, Jackson EF, Bohan TP, Butler IJ, Wolinsky JS. Regional in vivo proton magnetic resonance spectroscopy of brain. J Magn Reson. 1989;3:44-52.
52. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology. 1993;187:219-227.
53. Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med. 1998;39: 53-60.
54. Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology. 2000; 54:1344-1349.
55. Nordahl TE, Salo R, Possin K, Gibson DR, Flynn N, Leamon M, Galloway GP, Pfefferbaum A, Spielman DM, Adalsteinsson E, Sullivan EV. Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Psychiatry Res. 2002;116:43-52.
56. Sekine Y, Minabe Y, Kawai M, Suzuki K, Iyo M, Isoda H, Sakahara H, Ashby CR Jr, Takei N, Mori N. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms: a proton MRS study. Neuropsychopharmacology. 2002:27:453-461.
57. Taylor MJ, Alhassoon OM, Schweinsburg BC, Videen JS, Grant I. MR spectroscopy in HIV and stimulant dependence HNRC group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 2000;6:83-85.
58. Eberling JL, Roberts JA, Taylor SE, VanBrocklin HF, O'Neil JP, Nordahl TE. Effects of age and estrogen on aromatic L-amino acid decarboxylase activity in rhesus monkey brain. Neurobiol Aging. 2002;23:479-483.
59. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 1994;11:245-256.
60. First MB, Spitzer L, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York, NY: Biometrics Research Department; 1995.
61. Nelson HE. The National Adult Reading Test (NART). Windsor, Ontario: Nelson Publishing Co; 1982.
62. Frederick BB, Satlin A, Yurgelun-Todd DA, Renshaw PF. In vivo proton magnetic resonance spectroscopy of Alzheimer's disease in the parietal and temporal lobes. Biol Psychiatry. 1997;42:147-150.
63. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA. Proton magnetic resonance spectroscopy of vascular and Alzheimer-type dementia. Arch Neurol. 1996;53:678-680.
64. McKnight TR, Vigneron DB, Berger MS, McDermott MW, Lu Y, Nelson SJ. Evaluation of a novel Cho-NAA index as a tool for guiding biopsies of untreated glioma. Neuro-oncol. 2002;4:59.
65. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987;508:333-348.
66. Cohen G, Andreasen NC, Alliger R, Arndt S, Kuan J, Yuh WT, Ehrhardt J. Segmentation techniques for the classification of brain tissue using magnetic resonance imaging. Psychiatry Res. 1992;45:33-51.
67. Pfefferbaum A, Sullivan EV, Hedehus M, Lim KO, Adalsteinsson E, Moseley M. Age-related decline in brain white matter anisotropy measured with spatially corrected echo-planar diffusion tensor imaging. Magn Reson Med. 2000;44:259-268.
68. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci. 1990;600:649-661.
69. Pennypacker KR, Kassed CA, Eidizadeh S, O'Callaghan JP. Brain injury: prolonged induction of transcription factors. Acta Neurobiol Exp (Wars). 2000; 60:515-530.
70. Gao PP, Yue Y, Cerretti DP, Dryfux C, Zhou R. Ephrin-dependent growth and pruning of hippocampal axons. Proc Natl Acad Sci U S A. 1999;96:4073-4077.
71. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A. 1996;93:14065-14069.
72. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Wolf AP, Warner D, Zezulkova I, Cilento R. Inhibition of MAO B in the brains of smokers. Nature. 1996;379:733-738.
73. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, Lee GS, Huang J, Hahn EL, Mandelkern MA. Smoking-induced ventral striatum dopamine release. Am J Psychiatry. 2004;161:1211-1218.
74. Block W, Karitzky J, Traber F, Pohl C, Keller E, Mundegar RR, Lamericsh R, Rink H, Ries F, Schild HH, Jerusalem F. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol. 1998;55:931-936.
75. Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue EW, Steinbrich W. Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol. 2000;21:1220-1227.
76. Schocke MF, Berger T, Felber SR, Wolf C, Deisenhammer F, Kremser C, Seppi K, Aichner FT. Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy. Neuroimage. 2003;20:1253-1263.
77. Schubert F, Elster SF, Link A, Walzel M, Mientus S, Jaas J, Rinneberg H. Serial 1H-MRS in relapsing-remitting multiple sclerosis: effects of interferon-beta therapy on absolute metabolite concentrations. MAGMA. 2002;14:213-222.